Objectives: We assessed the ability of patients with autoimmune inflammatory diseases to successfully use the investigational AutoTouch (TM) reusable autoinjector as well as patient preference for AutoTouch (TM) versus the currently marketed single-use prefilled etanercept SureClick (R) autoinjector. Methods: Two multicenter studies were performed: a Home Use Study and a Patient Preference Study. In the Home Use Study, 77 patients with rheumatoid arthritis (RA) or psoriatic arthritis self-administered etanercept once weekly for 5 weeks. The primary end point was successful self-injection of etanercept via AutoTouch (TM). The Patient Preference Study was an open-label, randomized, 8-week crossover trial (4 weeks for each device) in 216 patients with RA or psoriasis (PsO). The primary end point was preference for AutoTouch (TM) versus SureClick (R). Results: In the Home Use Study, the proportion of successful self-injections with AutoTouch (TM) during weeks 1 through 5 was 97.8% (95% CI, 96.3. 99.3). In the Patient Preference Study, patients had a preference rate for AutoTouch (TM) of 41.7% (95% CI, 34.9-48.4) overall, 43.5% (95% CI, 35.5. 51.6) for patients with RA, and 36.8% (95% CI, 24.3. 49.4) for patients with PsO. Needle apprehension was not different at initiation of the autoinjectors, nor was there a difference between the injectors after 4 weeks. Overall, patients preferred AutoTouch T for ease of self-injecting, ease of pressing the start button, ease of following injection progress, and certainty of knowing when the injection was completed. SureClick (R) was preferred for fewer steps and experiencing less injection site discomfort or pain. Conclusion: The introduction of the AutoTouch (TM) will give patients a choice between two different autoinjectors for self-administration of etanercept.